Esplugues De Llobregat

• A study to assess the effect and safety of efgartigimod IV in participants from 12 years to less than 18 years of age with chronic Immune Th … Recruiting
  2025-521055-23-00 10 2025-10-07 Chronic Idiopathic thrombocytopenic purpura
• Clinical study of ruxolitinib and venetoclax for children with relapsed or refractory leukemia or lymphoma with mutations in the IL-7R/JAK-S … Recruiting
  2022-501867-42-01 9 2025-09-08 Acute Lymphoblastic Leukemia, in Relapse Lymphoblastic Lymphoma (Precu
• Medical-scientific study of dasatinib and venetoclax for children with relapsed or refractory leukemia or lymphoma with a mutation in the MA … Recruiting
  2022-501866-22-00 9 2025-08-26 Acute Lymphoblastic Leukemia, in Relapse Lymphoblastic Lymphoma (Precu
• A study to test if difelikefalin is safe in adolescents with itching related to long term kidney disease Recruiting
  2023-509909-74-00 4 2025-08-13 Pruritus
• A study to investigate the safety and efficacy of mRNA-3927 in participants with genetically confirmed propionic acidemia Recruiting
  2022-502910-10-00 7 2025-08-11 Propionic Acidemia
• A 2-Part, Randomized, Double-Blind, Placebo-Controlled Study in Participants with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping t … Recruiting
  2024-517499-39-00 7 2025-07-16 Duchenne Muscular Dystrophy
• A Phase 3, Randomized, Open-Label Study of Axatilimab Versus Best Available Therapy in Participants With Chronic Graft-Versus-Host Disease A … Recruiting
  2024-518973-32-00 5 2025-07-03 Chronic Graft-Versus-Host Disease
• A Study to Find Out How Nusinersen is Processed in the Body When Given Through the ThecaFlex DRx™ System in Adult and Pediatric Participants … Recruiting
  2024-514239-21-00 3 2025-05-21 Spinal Muscular Atrophy
• Long-term Follow-up study for relapsed/refractory (R/R) T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LL) patients previously treated … Recruiting
  2024-516617-20-00 5 2025-05-21 T-cell acute lymphoblastic Lymphoma
• Long-term Safety and Tolerability of TAK-881 in Subjects with Primary Immunodeficiency Diseases (PIDD) Recruiting
  2023-505946-24-00 5 2025-05-15 Primary Immunodeficiency Diseases
• Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With AS (Aspire) Recruiting
  2024-512600-19-00 5 2025-04-14 Angelman Syndrome
• A Phase 3 Double-blind Study to Evaluate the Efficacy and Safety of Oral Ozanimod Compared to Oral Fingolimod in Children and Adolescents wi … Recruiting
  2022-501332-42-00 5 2025-02-26 Relapsing Remitting Multiple Sclerosis
• The ENERGY 2 Study: A study to investigate if study drug INZ-701 increases survival in infants with ENPP1 Deficiency by preventing heart dys … Recruiting
  2024-512991-36-00 5 2024-10-24 Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency
• Open-label, Phase 3 Gene Delivery Study with SRP-9003 in LGMD 2E/R4 Subjects Recruiting
  2022-503112-17-00 5 2024-10-16 Limb-girdle muscular dystrophy, type 2E/R4 (LGMD2E/R4) or β-sarcoglyca
• Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects with Moderately to Severely Active Crohn's Dis … Recruiting
  2023-509618-12-00 5 2024-09-11 Crohn's Disease (CD)
• A study of anifrolumab in children and adolescents (5 to < 18 years old) with moderate to severe lupus to find the appropriate anifrolumab d … Recruiting
  2022-502289-25-00 5 2024-08-28 Moderate to Severe Active Systemic Lupus Erythematosus
• Efficacy and Safety of Vedolizumab Intravenous in Pediatric Chronic Pouchitis Recruiting
  2023-504773-20-00 5 2024-08-01 Active Chronic Pouchitis
• Crohn's Disease: Pharmacokinetics, Efficacy, and Safety of Risankizumab in Pediatric Subjects with Moderately to Severely Active Crohn's Dis … Recruiting
  2022-502050-14-00 5 2024-06-04 Crohn's disease
• Efficacy, safety, tolerability, and pharmacokinetics of risankizumab in pediatric subjects with active juvenile psoriatic arthritis Recruiting
  2023-506026-36-00 5 2024-04-29 Juvenile Psoriatic Arthritis
• Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and how Drug Move … Recruiting
  2022-501599-25-00 5 2024-03-19 juvenile idiopathic arthritis
• CHIP-AML22/Quizartinib sub-study: study of the safety and efficacy of quizartinib in children and adolescents with FLT3-ITD positive AML wit … Recruiting
  2023-505000-27-01 4 2023-12-29 newly diagnosed pediatric FLT3-ITD positive and NPM1 wild-type AML
• A Phase 3, Open-Label, Uncontrolled Study to Evaluate the Activity, Safety, Pharmacokinetics and Pharmacodynamics of Roxadustat for the Trea … Recruiting
  2022-501980-42-00 5 2023-12-21 Anemia associated with Chronic Kidney Disease
• Ulcerative Colitis: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects with Moderately to Severely Active Ulcerati … Recruiting
  2022-501788-41-00 5 2023-11-14 Ulcerative Colitis
• A Phase 3b Multicenter Open-label Trial of the Safety, Tolerability, and Efficacy of Tolvaptan in Infants and Children 28 days to less than … Recruiting
  2023-508218-41-00 5 2023-08-17 Autosomal Recessive Polycystic Kidney Disease

Showing 49–72 of 317 trials